Published in Circulation on February 17, 2004
Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol (2010) 1.77
CD36: implications in cardiovascular disease. Int J Biochem Cell Biol (2007) 1.62
Pleiotropic effects of pitavastatin. Br J Clin Pharmacol (2012) 0.99
CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharm Des (2012) 0.90
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One (2013) 0.88
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag (2009) 0.86
The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention. Am J Public Health (2013) 0.81
Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathol Commun (2013) 0.80
Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. Eur J Pharmacol (2009) 0.76
Pitavastatin: finding its place in therapy. Ther Adv Chronic Dis (2011) 0.75
Activation of Peroxisome Proliferator-activated Receptor γ (PPARγ) and CD36 Protein Expression: THE DUAL PATHOPHYSIOLOGICAL ROLES OF PROGESTERONE. J Biol Chem (2016) 0.75
Kimchi methanol extract and the kimchi active compound, 3'-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid, downregulate CD36 in THP-1 macrophages stimulated by oxLDL. J Med Food (2014) 0.75
Pitavastatin Differentially Modulates MicroRNA-Associated Cholesterol Transport Proteins in Macrophages. PLoS One (2016) 0.75
Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients. Int J Gen Med (2012) 0.75
The Role of CD36 in the Effect of Arginine in Atherosclerotic Rats. Med Sci Monit (2015) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med (2010) 4.42
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol (2013) 3.61
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med (2005) 3.45
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem (2002) 3.17
Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke (2013) 2.53
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (2004) 2.26
HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 2.25
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Inflammation in atherosclerosis and implications for therapy. Circulation (2004) 1.71
Managing a tachyarrhythmia in a patient with pheochromocytoma with landiolol, a novel ultrashort-acting beta-adrenergic blocker. Anesth Analg (2003) 1.68
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol (2010) 1.53
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes (2009) 1.46
Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli. Am J Physiol Heart Circ Physiol (2010) 1.46
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare? Circulation (2002) 1.42
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. AIDS Read (2007) 1.40
The editor's roundtable: JUPITER follow-up. Am J Cardiol (2011) 1.39
Update on statins: 2003. Circulation (2004) 1.37
Surgical results and related factors for ossification of posterior longitudinal ligament of the thoracic spine: a multi-institutional retrospective study. Spine (Phila Pa 1976) (2008) 1.31
Radiographic predictors for the development of myelopathy in patients with ossification of the posterior longitudinal ligament: a multicenter cohort study. Spine (Phila Pa 1976) (2008) 1.24
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord (2009) 1.18
Axial symptoms after cervical laminoplasty with C3 laminectomy compared with conventional C3-C7 laminoplasty: a modified laminoplasty preserving the semispinalis cervicis inserted into axis. Spine (Phila Pa 1976) (2005) 1.16
Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol (2008) 1.15
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol (2002) 1.14
CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol (2004) 1.13
A diagnostic support tool for lumbar spinal stenosis: a self-administered, self-reported history questionnaire. BMC Musculoskelet Disord (2007) 1.12
Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet (2009) 1.11
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J (2009) 1.04
Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation (2004) 1.03
Acute cervical spinal cord injury complicated by preexisting ossification of the posterior longitudinal ligament: a multicenter study. Spine (Phila Pa 1976) (2011) 1.03
Spinal cord shift on magnetic resonance imaging at 24 hours after cervical laminoplasty. Spine (Phila Pa 1976) (2009) 1.02
The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol (2003) 1.02
Adult scoliosis in syringomyelia associated with Chiari I malformation. Spine (Phila Pa 1976) (2002) 1.01
Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med (2003) 1.00
Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem (2009) 0.98
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol (2009) 0.97
Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem (2002) 0.95
Protein 3-nitrotyrosine in complex biological samples: quantification by high-pressure liquid chromatography/electrochemical detection and emergence of proteomic approaches for unbiased identification of modification sites. Methods Enzymol (2008) 0.95
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics (2004) 0.95
Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite. J Lipid Res (2006) 0.95
Building a transcontinental affiliation: a new model for academic health centers. Acad Med (2005) 0.94
Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol (2007) 0.94
Cervical range of motion and alignment after laminoplasty preserving or reattaching the semispinalis cervicis inserted into axis. J Spinal Disord Tech (2007) 0.93
Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. Am J Pathol (2013) 0.92
Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res (2003) 0.92
Tumour necrosis factor alpha-stimulated gene-6 inhibits osteoblastic differentiation of human mesenchymal stem cells induced by osteogenic differentiation medium and BMP-2. Biochem J (2006) 0.92
Surgical anatomy of the nuchal muscles in the posterior cervicothoracic junction: significance of the preservation of the C7 spinous process in cervical laminoplasty. Spine (Phila Pa 1976) (2008) 0.91
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem (2003) 0.90
Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med (2002) 0.90
Clinical significance of the redundant nerve roots of the cauda equina documented on magnetic resonance imaging. J Neurosurg Spine (2007) 0.88
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res (2012) 0.88
Improving lipid goal attainment: is it enough? Circulation (2009) 0.87
Genetic differences in the osteogenic differentiation potency according to the classification of ossification of the posterior longitudinal ligament of the cervical spine. Spine (Phila Pa 1976) (2011) 0.87
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. J Biol Chem (2007) 0.87
Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. Am J Physiol Cell Physiol (2004) 0.87
Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol (2006) 0.86
A functional RNAi screen for Runx2-regulated genes associated with ectopic bone formation in human spinal ligaments. J Pharmacol Sci (2008) 0.85
Statin therapy and the elderly: SAGE advice? Circulation (2007) 0.85
Simple foot tapping test as a quantitative objective assessment of cervical myelopathy. Spine (Phila Pa 1976) (2012) 0.85
Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10. Inflamm Res (2012) 0.85
Telomerase activity and telomere length of peripheral blood mononuclear cells in SLE patients. Lupus (2003) 0.84
Anatomic study of the semispinalis cervicis for reattachment during laminoplasty. Clin Orthop Relat Res (2005) 0.84
Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins Other Lipid Mediat (2006) 0.84
Centrally administered ghrelin potently inhibits water intake induced by angiotensin II and hypovolemia in rats. J Physiol Sci (2009) 0.84
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation (2002) 0.84
Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem (2012) 0.84
Dural damage due to a loosened hydroxyapatite intraspinous spacer after spinous process-splitting laminoplasty. Report of two cases. J Neurosurg Spine (2007) 0.83
Tyrosine nitration in prostaglandin H(2) synthase. J Lipid Res (2002) 0.83
Dexmedetomidine inhibits muscarinic type 3 receptors expressed in Xenopus oocytes and muscarine-induced intracellular Ca2+ elevation in cultured rat dorsal root ganglia cells. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.82
Past, present, and future standards for management of dyslipidemia. Am J Med (2004) 0.82
Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol Dis (2005) 0.82
Interobserver and intraobserver reliability of the classification and diagnosis for ossification of the posterior longitudinal ligament of the cervical spine. Eur Spine J (2012) 0.81